Lawsuits surrounding Merck's HPV vaccine Gardasil have been piling up for years now, but they've garnered increased public ...

A lawsuit involving Merck's Gardasil in Los Angeles has been adjourned and will reconvene with a new jury. Read more here.

SAN DIEGO, CA / ACCESS Newswire / February 20, 2025 / Robbins LLP reminds stockholders that a class action was filed on ...

Merck & Co.’s first trial over the safety of its blockbuster Gardasil cancer vaccine was cut short and rescheduled amid ...

Merck and a plaintiff have paused a trial over alleged injuries from the HPV vaccine Gardasil, with ties to HHS Secretary ...

Law Offices of Howard G. Smith announces that a class action lawsuit has been filed on behalf of investors who purchased Merck & Co ("Merck" or the "Company") (NYSE: MRK) securities between February 3 ...

Merck’s full-year 2025 revenue guidance fell short of what some analysts were expecting, at a range of $64.1 billion to $65.6 ...

Shares of Merck are sliding in early trading after the drugmaker surprised Wall Street with a lower-than-expected 2025 sales ...

Merck & Co. is facing its first jury trial over claims the company wrongfully marketed its lucrative Gardasil cancer vaccine as safe, the latest high-stakes litigation for the pharmaceutical giant.

Merck posted Q4 sales of $15.62 billion, driven by Keytruda's 19% growth. FY25 guidance lags estimates, citing Gardasil shipment pause in China and forex impact.

Merck’s stock tumbled 6% early Tuesday, after the drug company’s softer-than-expected guidance for the current year offset better-than-expected fourth-quarter earnings.